Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Clinical Trial 'Solidarity of Vaccines' began in Tunja and Duitama, Columbia
Medigen and Inovio are the two new biologicals against COVID-19 that will be applied to volunteers from these municipalities in Boyacá.

Tunja, November 2, 2021. (UACP). Tunja and Duitama were selected from eleven municipalities in the country and will be the cities that will start the study, taking into account the significant progress in the National Vaccination Plan, their epidemiological situation, their population and the logistics conditions for the study.
The World Health Organization, WHO and the Ministry of Health and Social Protection seek to find an effective treatment against COVID-19, through two new vaccines that will be applied to the largest number of volunteers in these two cities, thus betting on development of science in the department.

According to Luis Alexander Moscoso Osorio, Vice Minister of Health, this is an important study that takes into account two new vaccines that, in clinical trials and studies, have shown good efficacy.

"Now we are going to carry out phase three of the study, which allows us to study the prolongation and efficacy of vaccines over time. These are important studies, not only for Boyacá but for the country and the world, they will allow us to provide a greater supply of vaccines and thus achieve the long-awaited herd immunity, ”said the Vice Minister.

In turn, he indicated that conducting this trial in the department will provide tools for vaccines, the availability of biologicals, as well as the training of researchers and the vocation of collective help.

"This study began a few days ago in the two cities and in each of them there are already volunteers to carry out this trial, however, I invite people who have not yet been vaccinated to participate and contribute to the scientific development of the region" , Moscoso pointed out.

For his part, Jairo Mauricio Santoyo Gutiérrez, Secretary of Health of Boyacá, said that these new biologics are called Medigen, which is a recombinant protein Inovio DNA platform vaccine against COVID-19.

“The WHO has been clear that despite the fact that there are already vaccines available, it must bet on the development of new biologics to determine at some point which will be the most effective in the search to preserve the life of Boyacá and the community. in general ”, Santoyo Gutiérrez pointed out.

He added that once these vaccines are applied, it will be carried out by the research group, which in the case of Boyacá is the Clinical Research Center of the Colombia de Sanitas University Clinic, permanent monitoring of volunteers, in person and by telephone, at the 14 days after the administration of the first dose, 14 days after the second dose and between six to 12 months later, taking into account that these vaccines are of two doses, with an interval of 28 days.

"Today this study reaches Colombia and especially Boyacá with two cities, we are the only department that managed to include two cities to apply these doses and evaluate the effectiveness of two vaccines to have them on the market very soon and thus find more options and reach more population vaccinated against COVID-19 ”, assured the head of the department's Health portfolio.
https://www-boyaca-gov-co.translate.goog/inicio-ensayo-clinico-solidaridad-de-vacunas-en-tunja-y-duitama/?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=nui